BofA raised the firm’s price target on Apellis (APLS) to $24 from $23 and keeps a Neutral rating on the shares. Apellis has not provided sales guidance for Syfovre, which would provide more visibility on expectations for the Syfovre launch at this point, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Justify Buy Rating
- Apellis Pharmaceuticals: Sustained Growth Potential and Market Resilience Justify Buy Rating
- Apellis price target raised to $26 from $25 at Morgan Stanley
- Cautious Optimism: Apellis Pharmaceuticals’ Strategic Moves and Market Uncertainties Justify Hold Rating
- Strategic Financial Maneuvers and Market Opportunities Drive Buy Rating for Apellis Pharmaceuticals